RxDoctor Payments Data

Husam Ali, MD

Family Medicine · Burbank, ILNPI 1912444209

Payments from drug & device makers

$566in general payments, 2019–2025

Across 27 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$89
  • Neurocrine Biosciences, Inc.$88
  • Lilly USA, LLC$64
  • Novartis$41
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$40
  • E.r. Squibb & Sons, L.L.C.$38
  • plus $206 from 8 others

What the payments were for

  • Food & beverage$566100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$566 in reported general payments places this provider in the 65th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$477,646
Medicare patients
388
Services billed
4,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban535$129,712
Invega SustennaPaliperidone Palmitate11$41,358
EntrestoSacubitril/Valsartan107$27,066
XifaxanRifaximin16$23,840
MounjaroTirzepatide12$21,343
TradjentaLinagliptin52$16,653
JardianceEmpagliflozin56$15,511
TrulicityDulaglutide18$14,943
XareltoRivaroxaban32$10,558
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,143
Atorvastatin Calcium731$9,719
FarxigaDapagliflozin Propanediol26$7,661
Enoxaparin Sodium65$7,564
MyrbetriqMirabegron29$6,757
RestasisCyclosporine19$6,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$64$36,28630 claims
NovartisEntresto$41$27,066107 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$33$23,84016 claims
AstraZenecaFarxiga, Brilinta, Symbicort$25$16,11671 claims
AbbVieRestasis$26$6,65119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Burbank

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →